ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...
GlobalData on MSN
Novocure receives CE mark for Optune Pax device
The decision was based on findings from the Phase III PANOVA-3 clinical trial.
The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
“The leading news in the quarter was the FDA approval and subsequent U.S. launch of Optune Pax for patients with locally advanced pancreatic cancer.” (Executive Chairman William Doyle) “In the 7 weeks ...
(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results